MarginsXMarginsX
Home › Markets › Health Care › BMRN

BioMarin Pharmaceutical Inc. (BMRN)

BMRN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$57.99
+1.33% on the day
Market cap
$11.2B
Large cap
Revenue · 2025
$3.2B
+12.9% on 2024
Net income · 2025
$348.9M
10.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1048477/000104847726000004/0001048477-26-000004-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBMRN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year1999
SEC CIK0001048477
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$3.2B
Net income$348.9M
Operating income$409.5M
Net margin10.8%
Operating margin12.7%
Revenue growth+12.9%
Cash$1.3B
Total assets$7.6B
P/E (computed)32.2×
P/S (computed)3.5×

Warning signs

Cash runway
Cash-flow positive
$736.0M cash at September 30, 2026
Share count, 1 year
+0.8%
2025-10-23 to 2026-10-26 · +2.8% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$4.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$736.0M cash; operating cash flow $169.2M a quarter.Report 2026-09-30
Shares outstanding193,694,734 (2026-10-26); 192,114,344 a year earlier; 188,368,171 three years earlier.Cover page 2026-10-26
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, San Francisco, California, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $4.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.0B-$122.8M$188.2M$736.0M$4.2B$3.7B10-Q 2026-11-03
Q2 2026
2026-06-30
$989.7M$44.8M$168.1M$874.0M$4.2B$3.4B10-Q 2026-08-06
Q1 2026
2026-03-31
$766.2M$105.5M$220.7M$2.2B$1.4B$3.2B10-Q 2026-05-05
Q4 2025
2025-12-31
$874.6M-$46.6M$99.6M$1.3B$597.2M$3.2B10-K 2026-02-26
Q3 2025
2025-09-30
$776.1M-$30.7M$368.7M$1.3B$596.7M$3.1B10-Q 2026-11-03
Q2 2025
2025-06-30
$825.4M$240.5M$185.3M$1.2B$596.2M$3.1B10-Q 2026-08-06
Q1 2025
2025-03-31
$745.1M$185.7M$174.4M$1.0B$595.6M$3.0B10-Q 2026-05-05
Q4 2024
2024-12-31
$747.3M$124.9M$185.6M$942.8M$595.1M$2.9B10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52017-08-09
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-03
Latest current report8-K2026-11-02
Latest proxyDEFA14A2026-04-21

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.1%
1 month+5.2%
3 months-16.5%
Year to date-3.7%
1 year+5.6%
From 52-week high-18.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
RDYDr. Reddy's Laboratories Ltd$14.70-0.27%$12.3B
MDGLMadrigal Pharmaceuticals Inc.$423.96-0.80%$9.8B
ELANElanco Animal Health Incorporated$26.41-1.38%$13.2B
TGTXTG Therapeutics Inc.$62.76-2.71%$9.5B
SMMTSummit Therapeutics Inc. Common Stock$11.82-16.47%$9.5B
SYRESpyre Therapeutics Inc.$99.37-4.45%$9.4B
PRAXPraxis Precision Medicines Inc.$310.27-5.44%$8.7B
BBIOBridgeBio Pharma Inc.$77.36-1.20%$15.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier